Clinical trial

The Association Between Anti-osteoporosis Medications and Lowered All Cause Mortality After Osteoporotic Fractures

Name

Osteoporosis and Mortality

Description

Osteoporotic fracture is a common public-health problem in the whole world. Although postfracture usage of anti-osteoporosis medications, may reduce mortality, recent results have been inconsistent. The investigators aim to examine associations between osteoporosis medication and mortality in older adults and any type of fracture patients. The investigators also aim to discuss the pleiotropic effects of different types of anti-osteoporosis medications.

Trial arms

Trial start

2020-11-01

Estimated PCD

2021-09-30

Trial end

2021-10-31

Status

Completed

Treatment

Anti-osteoporosis medications

Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).

Arms:

Did not use osteoporosis medication, Used osteoporosis medication

Other names:

Bisphosphonates, Denosumab, Hormone-related therapy, Bone-building medication

Size

216155

Primary endpoint

Number of deaths with and without anti-osteoporotic therapy after hip fracture surgery

12 years

Number of deaths with or without anti-osteoporosis therapy after hip or vertebral fracture surgery among older adults

12 years

Number of deaths with and without bisphosphonates after hip or spine fracture surgery

12 years

Number of deaths with different types of anti-osteoporosis treatments after post-fracture

12 years

Number of deaths in five leading causes of death with and without anti-osteoporosis treatment after post-fracture

12 years

Eligibility criteria

Inclusion Criteria: * Newly diagnosed osteoporosis and hip fracture are defined as a claim record from the NHIRD between 2009 and 2017. Exclusion Criteria: * Patients with a diagnosis of osteoporosis or osteoporotic fractures in 2008 or before were excluded.

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 216155, 'type': 'ACTUAL'}}

Updated at

2023-04-04

1 organization

1 product

6 indications

Organization

National Cheng-Kung University Hospital

Product

Anti-osteoporosis medications

Indication

Osteoporosis

Indication